

La Renon

# CONTROL

## THE CHAOS



With The **Ultimate Antiemetic**

# DOPNAUZ

AMISULPRIDE INJECTION 5 mg / 2 ml


\*Creative Visualization

## BACKGROUND:

- ▶ Nausea and vomiting are common responses to surgery, chemotherapy, or motion sickness, greatly impact patients well-being. These symptoms can be triggered by various factors, including stimulation of the chemoreceptor trigger zone (CTZ) in the brainstem, which initiates the reflexive response of emesis.
- ▶ Intravenous administration of amisulpride (dopamine D<sub>2</sub> and D<sub>3</sub> receptor antagonists) at low doses effectively manage nausea and vomiting, ensuring patient comfort and satisfaction.



## MULTIPLE PATHWAYS INVOLVED IN THE PATHOPHYSIOLOGY OF NAUSEA & VOMITING:




# THE CHAOS

## INTRODUCING DOPAMINE ANTAGONIST AMISULPRIDE AS A NOVEL ANTI-EMETIC

### AMISULPRIDE INJECTION IS EFFECTIVE AS <sup>2,3,4,5</sup>

- Monotherapy Prophylaxis
- Combination Prophylaxis with Ondansetron/Dexamethasone
- Treatment Option with No Prior Prophylaxis
- Treatment Option with Failed Prior Prophylaxis

### EFFICACY DATA <sup>6,7,8,9</sup>



### SAFETY DATA

- Intravenous amisulpride does not meaningfully prolong the QTc interval at effective doses.
- Amisulpride showed no evidence of the toxicities associated with other commonly used antiemetics, notably cardiac and extrapyramidal events, constipation, sedation, infection, and diabetogenesis.<sup>10,11,12</sup>

# DOPNAUZ

AMISULPRIDE INJECTION 5 mg / 2 ml



CONTROL  
THE CHAOS

## DESCRIPTION:

Dopnauz is a single-dose vial containing amisulpride, available in a strength of 5 mg/2 ml (2.5 mg/ml). Amisulpride acts as a selective antagonist of dopamine-2 (D<sub>2</sub>) and dopamine-3 (D<sub>3</sub>) receptors, effectively preventing nausea and vomiting and enhancing the quality of life of the patients.

## USAGE:

- **Prevention of Nausea and Vomiting:** Either alone or in combination with an antiemetic of a different class.
- **Treatment of Nausea and Vomiting:** In patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.

## MECHANISM OF ACTION:

- Amisulpride is a selective dopamine-2 (D<sub>2</sub>) and dopamine-3 (D<sub>3</sub>) receptor antagonist. D<sub>2</sub> receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings.
- Activation of CTZ relays stimuli to the vomiting center which is involved in emesis.

## DOSAGE AND ADMINISTRATION:

- **Prevention of Nausea and Vomiting:** Either alone or in combination with another antiemetic: 5 mg as a single intravenous dose infused over 1 to 2 minutes at the time of induction of anaesthesia.
- **Treatment of Nausea and Vomiting:** 10 mg as a single intravenous dose infused over 1 to 2 minutes in the event of nausea and/or vomiting after a surgical procedure.

## PREPARATION & ADMINISTRATION:

- Dilution of Amisulpride Injection is not required before administration.
- Amisulpride Injection is chemically and physically compatible with Water for Injection, 5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer's Solution (also known as Ringer's Lactate Solution, Compound Sodium Lactate Solution, and Hartmann's Solution).
- Any of which may be used to flush an intravenous line before or after administration of Amisulpride Injection.

## KEY ADVANTAGES:

- Amisulpride, as a selective D<sub>2</sub>/D<sub>3</sub> receptor antagonist, offers a pharmacological treatment option from a different class than commonly used prophylaxis agents.
- Clear solution and easy to infuse in 1 to 2 mins.
- Compatible with dextrose, NaCl, WFI.
- Easy to add on to existing Nausea and Vomiting management options.
- Works well both in adults and in elderly population.
- Superior side effect profile.
- Devoid of any major limitation.

## PRESENTATION:

Available as 5 mg/2 mL (2.5 mg/mL) in a single-dose vial.

### References:

1. Medical Journal Armed Forces India, 2022 Sep 1;78:S158-62
2. Anesthesia & Analgesia, 2019 Jun 1;128(6):1098-1105.
3. Anesthesiology. 2019 Feb;130(2):203-12.
4. Anesthesiology. 2017 Feb;126(2):268-75.
5. Anesthesiology. 2018 Jun;128(6):1099-106.
6. Anesthesiology. 2017;126(2):268-275.11
7. Anesthesiology. 2018 Jun;128(6):1099-1106.7
8. Anesth Analg. 2019; 128(6): 1098-1105.3
9. Anesthesiology. 2019; 130(2): 203-212.5
10. J Clin Pharmacol (2017) 83 339-348
11. [https://www.accessdata.fda.gov/scripts/cder/ob/search\\_product.cfm](https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm)
12. International clinical psychopharmacology. 1999 Jul 1;14(4):209-18



Scan for more  
Prescribing Information

## La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad-380015, Gujarat, India.  
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998  
E-mail: info@larenon.com | Web: www.larenon.com

Hello

I am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_